We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: R1 RCM Inc. is a provider of technology-driven solutions which transform the patient experience and financial performance of hospitals, health systems and medical groups. R1 RCM Inc., formerly known as PROJECT ROADRNR, is based in MURRAY, Utah.
- Recent RCM Stock Price: $13.17
- Yearly Gain for RCM stock: -3.55%
- Market Cap for RCM stock: $5.53B
- P/E Ratio for RCM stock: 1316.5
Will RCM's stock price go up? Is there an accurate RCM stock forecast available?
TipRanks.com reports that R1 RCM Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $17.60. The target pricing ranges from a high RCM forecast of $20 down to a low forecast of $16. R1 RCM Inc. (RCM)’s last closing stock price was $13.17 which would put the average price target at 33.64% upside.
In addition, TradingView issued a rating for RCM stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RCM stock.
Other analysts covering RCM include:
- Michael Cherny of Leerink Partners issued a Buy rating with the price target of $17 on 1 week ago
- Sean Dodge of RBC Capital issued a Buy rating with the price target of $19 on 1 week ago
- Jailendra Singh of Truist Financial issued a Hold rating with the price target of $16 on 2 weeks ago
- Charles Rhyee of TD Cowen issued a Buy rating with the price target of $20 on 2 weeks ago
If you are wondering if RCM is a good stock to buy, here are 3rd party ratings for RCM stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Sell, Top 36% (90 out of 251)
What is the sentiment on the street regarding R1 RCM Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for RCM stock: Bullish
- Blogger Consensus for RCM stock:
- Media Buzz for RCM stock: Strong Buy
- Insider Signal for RCM stock: Selling
- Investor Sentiment for RCM stock: Negative
- Hedge Fund signal for RCM stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on RCM stock including scouring the social networks like RCM StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RCM stock chart >>
Summary: Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA.
- Recent ARCT Stock Price: $33.25
- Yearly Gain for ARCT stock: 116.58%
- Market Cap for ARCT stock: $894.80M
- P/E Ratio for ARCT stock: -29.16
Will ARCT's stock price go up? Is there an accurate ARCT stock forecast available?
TipRanks.com reports that Arcturus Therapeutics Holdings Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $84.80. The target pricing ranges from a high ARCT forecast of $87 down to a low forecast of $140. Arcturus Therapeutics Holdings Inc. (ARCT)’s last closing stock price was $33.25 which would put the average price target at 155.04% upside.
In addition, TradingView issued a rating for ARCT stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ARCT stock.
Other analysts covering ARCT include:
- Whitney Ijem of Canaccord Genuity issued a Buy rating with the price target of $87 on 1 week ago
- Ed Arce of H.C. Wainwright issued a Buy rating with the price target of $60 on 1 week ago
- Yanan Zhu of Wells Fargo issued a Buy rating with the price target of $58 on 1 week ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $140 on 1 week ago
If you are wondering if ARCT is a good stock to buy, here are 3rd party ratings for ARCT stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 33% (84 out of 251)
What is the sentiment on the street regarding Arcturus Therapeutics Holdings Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARCT stock: Bearish
- Blogger Consensus for ARCT stock:
- Media Buzz for ARCT stock: Neutral
- Insider Signal for ARCT stock: Selling
- Investor Sentiment for ARCT stock: Positive
- Hedge Fund signal for ARCT stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on ARCT stock including scouring the social networks like ARCT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARCT stock chart >>
Summary: Nyxoah SA is a medical technology company. It focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea. Nyxoah SA is based in Belgium.
- Recent NYXH Stock Price: $15.57
- Yearly Gain for NYXH stock: 147.14%
- Market Cap for NYXH stock: $446.26M
- P/E Ratio for NYXH stock: -8.51
Will NYXH's stock price go up? Is there an accurate NYXH stock forecast available?
TipRanks.com reports that Nyxoah S.A. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $20.42. The target pricing ranges from a high NYXH forecast of $27 down to a low forecast of $13.08. Nyxoah S.A. (NYXH)’s last closing stock price was $15.57 which would put the average price target at 31.12% upside.
In addition, TradingView issued a rating for NYXH stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on NYXH stock.
Other analysts covering NYXH include:
- Jonathan Block of Stifel Nicolaus issued a Buy rating with the price target of $27 on 9 hours ago
- Suraj Kalia of Oppenheimer issued a Buy rating with the price target of $20 on 9 hours ago
- Edward White of H.C. Wainwright issued a Buy rating with the price target of $22 on 9 hours ago
- David Rescott of Robert W. Baird issued a Hold rating with the price target of $13.08 on 2 weeks ago
If you are wondering if NYXH is a good stock to buy, here are 3rd party ratings for NYXH stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 37% (94 out of 251)
What is the sentiment on the street regarding Nyxoah S.A.? (Current ratings compiled by TipRanks.com)
- News Sentiment for NYXH stock: Bearish
- Blogger Consensus for NYXH stock:
- Media Buzz for NYXH stock: Neutral
- Insider Signal for NYXH stock: -
- Investor Sentiment for NYXH stock: Positive
- Hedge Fund signal for NYXH stock: High Risk
The stock market is extremely volatile, and you need to do your own research on NYXH stock including scouring the social networks like NYXH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NYXH stock chart >>
Summary: Tempest Therapeutics Inc. is a clinical-stage oncology company developing potentially first-in-class therapeutics which combines both targeted and immune-mediated mechanisms. Tempest Therapeutics Inc., formerly known as Millendo Therapeutics Inc., is based in Calif.
- Recent TPST Stock Price: $3.53
- Yearly Gain for TPST stock: 180.16%
- Market Cap for TPST stock: $67.94M
- P/E Ratio for TPST stock: -1.6
Will TPST's stock price go up? Is there an accurate TPST stock forecast available?
TipRanks.com reports that Tempest Therapeutics, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $18.60. The target pricing ranges from a high TPST forecast of $8 down to a low forecast of $10. Tempest Therapeutics, Inc. (TPST)’s last closing stock price was $3.53 which would put the average price target at 426.91% upside.
In addition, TradingView issued a rating for TPST stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on TPST stock.
Other analysts covering TPST include:
- George Farmer of Scotiabank issued a Buy rating with the price target of $13 on 1 week ago
- Maury Raycroft of Jefferies issued a Buy rating with the price target of $15 on 1 month ago
- Aydin Huseynov of Ladenburg Thalmann & Co. issued a Buy rating with the price target of $10 on 4 months ago
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $8 on 4 months ago
If you are wondering if TPST is a good stock to buy, here are 3rd party ratings for TPST stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 38% (96 out of 251)
What is the sentiment on the street regarding Tempest Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for TPST stock: Bearish
- Blogger Consensus for TPST stock:
- Media Buzz for TPST stock: Neutral
- Insider Signal for TPST stock: Selling
- Investor Sentiment for TPST stock: Positive
- Hedge Fund signal for TPST stock: High Risk
The stock market is extremely volatile, and you need to do your own research on TPST stock including scouring the social networks like TPST StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TPST stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================